Abstract
Idiopathic inflammatory myopathies are characterized by muscle weakness, elevation in serum muscle enzyme levels, electromyography abnormalities, presence of Myositis Specific Autoantibodies (MSAs) and findings of inflammation on muscle biopsy. Immune-mediated necrotizing myopathy (IMNM) is a subset of IIM that is often resistant to standard immunosuppressive therapy, requiring multiple combinations of therapeutic agents. We present a case of a middle-aged man with positive anti-Signal Recognition Particle (SRP) IMNM who responded to abatacept and tacrolimus after failing standard of care treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
